{ "items": [ "\n\n
\n \n 4 February 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nThe Oxford Vaccine Group is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.
\n \n\n\n \n 27 January 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n \n \nToday, Andrew Pollard, Professor of Pediatric Infection and Immunity at the University of Oxford, and chief investigator of the trials of the ChAdOx1 nCoV-19 coronavirus vaccine, volunteered his time to help deliver live-saving Covid vaccinations at the newly opened NHS Vaccine Centre at the Kassam Stadium, Oxford.
\n \n\n\n \n 13 January 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \n \n \n\n\n \n 7 January 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Public Engagement\n \n \n\n \n\n\n
\n \n\n \n \n \nProfessor Katie Ewer (The Jenner Institute) and Dr Maheshi Ramasamy (Oxford Vaccine Group) appeared on ITV's This Morning on Wednesday 6 January to talk about their work developing the ChAdOx1 nCoV-19 coronavirus vaccine, all while juggling the demands of young families and home-schooling.
\n \n\n\n \n 17 December 2020\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Publication\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nResearchers from the University of Oxford have published further data from the Phase I/II clinical trials of the ChAdOx1 nCoV-19 coronavirus vaccine, evidencing the decision to move to a two-dose regimen in ongoing phase III trials, and how ChAdOx1 nCov-19 induces broad antibody and T cell functions.
\n \n\n\n \n 10 December 2020\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n \n \nUniversity of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.
\n \n\n\n \n 7 December 2020\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n \n \nA special concert to say thank you and pay tribute to the achievements of the Oxford vaccine team has been recorded at the Sheldonian Theatre for a film screening in time for Christmas
\n \n\n\n \n 24 November 2020\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n \n \nThe University of Oxford team who have developed a COVID-19 vaccine in record time have been shortlisted for the Excellence in Healthcare Award at the NHS Parliamentary Awards.
\n \n\n\n \n 23 November 2020\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Publication\n \n \n\n \n\n\n
\n \n\n \n \n \nThe University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.
\n \n\n\n \n 19 November 2020\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Publication\n \n \n\n \n\n\n
\n \n\n \n \n \nThe ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age.
\n \n\n\n \n 23 September 2020\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n \n \nPublic trust is key to a successful immunisation programme, writes Samantha Vanderslott in a piece for The Conversation.
\n \n\n\n \n 20 July 2020\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n \n \nA team of scientists at Oxford Vaccine Group (Department of Paediatrics) and Oxford University\u2019s Jenner Institute has taken the next step towards the discovery of a safe, effective and accessible vaccine against coronavirus.
\n \n\n\n \n 16 July 2020\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n \n \nFirst results of the What\u2019s the STORY (Serum Testing Of Representative Youngsters) trial indicate higher resilience of children to COVID-19 compared to other respiratory illnesses.
\n \n\n\n \n 1 July 2020\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nParticipants in South Africa\u2019s first clinical trial for a vaccine against COVID-19 are to be vaccinated this week.
\n \n\n\n \n 1 July 2020\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nVolunteers have begun taking part in Latin America\u2019s first clinical trial for a vaccine against COVID-19.
\n \n\n\n \n 26 June 2020\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n \n \nThe Duke of Cambridge visits the University of Oxford\u2019s Oxford Vaccine Centre, to learn more about their work to establish a viable vaccine against COVID-19.
\n \n\n\n \n 15 June 2020\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nAstraZeneca has reached an agreement with Europe\u2019s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford\u2019s COVID-19 vaccine, with deliveries starting by the end of 2020.
\n \n\n\n \n 22 May 2020\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nOxford Vaccine Group researchers have begun recruiting for the next phase in human trials of a COVID-19 vaccine in human volunteers.
\n \n\n\n \n 18 May 2020\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nThe Government has announced \u00a365.5 million of new funding for the vaccine being developed at the Oxford Vaccine Group as coronavirus vaccine trials accelerate.
\n \n\n\n \n 30 April 2020\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nThe University of Oxford has today announced an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the Oxford Vaccine Group.
\n \n\n